Malaria investigational vaccine

R21* is a protein-based investigational vaccine developed by the University of Oxford, using our Matrix-M™ adjuvant technology.¹ This investigational vaccine is specifically designed to help protect against malaria.

Malaria remains a significant global burden of disease,² infecting nearly 230 million people worldwide in 2019 alone, with an estimated 409,000 deaths. New, effective vaccines are urgently needed to address this threat.¹

R21 has been evaluated in safety and efficacy trials in both adults and children.

*Investigational vaccine created and trial sponsored by University of Oxford in collaboration with Serum Institute of India, with Matrix-M adjuvant.